Boston Scientific earns FDA approval for Spectra WaveWriter SCS System — 5 notes

Written by Megan Wood | January 12, 2018 | Print  |

The FDA approved Boston Scientific's Spectra WaveWriter Spinal Cord Stimulator System.

Here are five notes:

 

1. The company reports it's the first-ever FDA-approved system to offer paresthesia-based and sub-perception therapy at the same time.

 

2. The Spectra WaveWriter allows patients to either use both therapies simultaneously or use each separately for different pain points.

 

3. Patients use the system's remote control to submit real-time feedback.

 

4. Various studies support the Spectra WaveWriter, highlighting the benefits of the combined paresthesia-based and sub-perception therapies.

 

5. The SCS provides chronic pain patients a non-opioid treatment alternative.

 

More articles on devices:
OrthAlign welcomes Dr. Steven Haas to executive surgeon council advisory board: 5 things to know
Comparing time off – how many vacation weeks do physicians take?
PARS Brain and Spine Institute opens diner to support charity — 5 highlights
 

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months